You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 330 Combination therapy with stem cell derived natural killer cells and monoclonal antibodies leads to potent ADCC through engagement of endogenouse CD16

Citation Tools

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Cellular Therapies
330 Combination therapy with stem cell derived natural killer cells and monoclonal antibodies leads to potent ADCC through engagement of endogenouse CD16

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Georgoudaki A, Lamers-Kok N, Vliet AV, et al
330 Combination therapy with stem cell derived natural killer cells and monoclonal antibodies leads to potent ADCC through engagement of endogenouse CD16
Journal for ImmunoTherapy of Cancer 2023;11:doi: 10.1136/jitc-2023-SITC2023.0330